On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
Hosted on MSN16d
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its ...
This was the stock's second consecutive day of losses.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback